
Ginkgo Bioworks rose 9.3% from $7.78 to $8.50, behind the S&P 500's +11.2%. Its worst day was Feb 27 (−30.5%), and its low came Mar 30 at $5.48.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Ginkgo Bioworks shares rose 21.4%, while the S&P 500 rose 1.9%.
+21.4%, the year's best day · S&P 500 +1.9%
EPS of $-1.41 missed the $-1.39 estimate on $33.3M revenue (est. $37.3M).
Story events cover the past 12 months · Times ET
−30.5%, the year's worst day · S&P 500 −0.5%
Ginkgo Bioworks closed at its lowest level of the year, 29.6% below where the year started.
−7.6% · S&P 500 −0.3%
EPS of $-1.39 missed the $-1.34 estimate on $19.5M revenue (est. $42.4M).
−13.5% · S&P 500 +0.8%
EPS of $-0.92 missed the $-0.70 estimate on $20.2M revenue (est. $24.8M).
−9.3% · S&P 500 −0.2%
Ginkgo Bioworks shares rose 18.1%, while the S&P 500 rose 0.2%.
+18.1% · S&P 500 +0.2%
Ginkgo Bioworks shares rose 19.5%, while the S&P 500 fell 0.1%.
+19.5% · S&P 500 −0.1%
Ginkgo Bioworks closed at its highest level of the year, 92.5% above where the year started.
+21.3% · S&P 500 +0.7%
Ginkgo Bioworks shares rose 18.2%, while the S&P 500 rose 0.3%.
+18.2% · S&P 500 +0.3%
EPS of $-0.64 missed the $-0.55 estimate on $27.7M revenue (est. $21.3M).
+13.4% · S&P 500 +0.3%
Where it ended: a close of $8.50 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.82, revenue est. $22.8M).
Nothing in the past 12 months.
All DNA dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for DNA and SPY from Benzinga historical bars. Not investment advice.